Personalis Revenue 2018-2026 | PSNL
Personalis revenue from 2018 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
Personalis Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $70 |
| 2024 | $85 |
| 2023 | $73 |
| 2022 | $65 |
| 2021 | $85 |
| 2020 | $79 |
| 2019 | $65 |
| 2018 | $38 |
| 2017 | $9 |
|
Personalis Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-06-30 | $22 |
| 2026-03-31 | $15 |
| 2025-12-31 | $17 |
| 2025-09-30 | $14 |
| 2025-06-30 | $17 |
| 2025-03-31 | $21 |
| 2024-12-31 | $17 |
| 2024-09-30 | $26 |
| 2024-06-30 | $23 |
| 2024-03-31 | $20 |
| 2023-12-31 | $20 |
| 2023-09-30 | $18 |
| 2023-06-30 | $17 |
| 2023-03-31 | $19 |
| 2022-12-31 | $17 |
| 2022-09-30 | $15 |
| 2022-06-30 | $18 |
| 2022-03-31 | $15 |
| 2021-12-31 | $21 |
| 2021-09-30 | $22 |
| 2021-06-30 | $22 |
| 2021-03-31 | $21 |
| 2020-12-31 | $20 |
| 2020-09-30 | $20 |
| 2020-06-30 | $19 |
| 2020-03-31 | $19 |
| 2019-12-31 | $18 |
| 2019-09-30 | $17 |
| 2019-06-30 | $16 |
| 2019-03-31 | $14 |
| 2018-09-30 | $12 |
| 2018-06-30 | $9 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |